BBIO BridgeBio Pharma Inc

$49.08

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/22/2025

About BridgeBio Pharma Inc

BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.

Website: https://bridgebio.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1743881
Address
421 KIPLING STREET, PALO ALTO, CA, US
Valuation
Market Cap
$6.44B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
123.68
Performance
EPS
$-2.88
Dividend Yield
—
Profit Margin
-241.40%
ROE
-1790.00%
Technicals
50D MA
$33.70
200D MA
$28.81
52W High
$39.47
52W Low
$21.62
Fundamentals
Shares Outstanding
190M
Target Price
$54.06
Beta
1.08

BBIO EPS Estimates vs Actual

● Estimated
● Actual

BBIO News & Sentiment

Aug 11, 2025 • Benzinga SOMEWHAT-BULLISH
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition - Helix Acquisition Corp ( NASDAQ:HLXB )
Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, completed on August 11, 2025 Closed concurrent $261 million private investment in public equity ( "PIPE" ) , led by Cormorant
Aug 11, 2025 • GlobeNewswire SOMEWHAT-BULLISH
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition
BBOT Debuts as Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition ...
Aug 06, 2025 • GlobeNewswire NEUTRAL
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics
BOSTON & SOUTH SAN FRANCISCO, Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Helix Acquisition Corp. II ( "Helix" ) ( Nasdaq: HLXB ) , a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, and TheRas, Inc. ( d/b/a BridgeBio Oncology Therapeutics ) ( "BBOT" ) , a ...
Aug 06, 2025 • Benzinga NEUTRAL
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics - BridgeBio Pharma ( NASDAQ:BBIO ) , Helix Acquisition Corp ( NASDAQ:HLXB )
Gross proceeds of approximately $120 million from trust account and approximately $261 million from PIPE financing to be available to the combined company at the closing 2nd lowest redemption rate for a biotech de-SPAC transaction since 2022
Aug 05, 2025 • Zacks Commentary NEUTRAL
BridgeBio Pharma ( BBIO ) Reports Q2 Loss, Beats Revenue Estimates
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -14.46% and +14.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 05, 2025 • Benzinga SOMEWHAT-BULLISH
Check Out What Whales Are Doing With BBIO - BridgeBio Pharma ( NASDAQ:BBIO )
Investors with a lot of money to spend have taken a bullish stance on BridgeBio Pharma BBIO. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
Sentiment Snapshot

Average Sentiment Score:

0.162
50 articles with scored sentiment

Overall Sentiment:

Bullish

BBIO Reported Earnings

Apr 30, 2025
Mar 31, 2025 (Pre market)
-0.1 Surprise
  • Reported EPS: $-0.99
  • Estimate: $-0.89
  • Whisper: —
  • Surprise %: -11.1%
Feb 20, 2025
Dec 31, 2024 (Pre market)
-0.28 Surprise
  • Reported EPS: $-1.37
  • Estimate: $-1.09
  • Whisper: —
  • Surprise %: -26.1%
Nov 01, 2024
Sep 30, 2024 (Pre market)
0.12 Surprise
  • Reported EPS: $-0.86
  • Estimate: $-0.98
  • Whisper: —
  • Surprise %: 12.3%
Aug 01, 2024
Jun 30, 2024 (Pre market)
0.67 Surprise
  • Reported EPS: $-0.39
  • Estimate: $-1.06
  • Whisper: —
  • Surprise %: 63.2%
May 02, 2024
Mar 31, 2024 (Pre market)
0.51 Surprise
  • Reported EPS: $-0.20
  • Estimate: $-0.71
  • Whisper: —
  • Surprise %: 71.8%
Feb 22, 2024
Dec 31, 2023 (Pre market)
-0.05 Surprise
  • Reported EPS: $-0.96
  • Estimate: $-0.91
  • Whisper: —
  • Surprise %: -5.5%
Nov 02, 2023
Sep 30, 2023 (Pre market)
-0.26 Surprise
  • Reported EPS: $-1.08
  • Estimate: $-0.82
  • Whisper: —
  • Surprise %: -31.7%
Aug 03, 2023
Jun 30, 2023 (Pre market)
-0.15 Surprise
  • Reported EPS: $-0.98
  • Estimate: $-0.83
  • Whisper: —
  • Surprise %: -18.1%
May 04, 2023
Mar 31, 2023 (Pre market)
-0.09 Surprise
  • Reported EPS: $-0.92
  • Estimate: $-0.83
  • Whisper: —
  • Surprise %: -10.8%

Financials